ClinicalTrials.gg
Active, not recruitingNCT07442630Updated Mar 2, 2026

Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides

A Phase 4 interventional study of Pitavastatin 4mg and Ezetimibe 10 mg in Hypercholesterolemia, sponsored by JW Pharmaceutical. Active, not recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by JW Pharmaceutical · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Aug 2023, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
68th of 97
88 · median 148
Started
2023
the only one that year
Phase 4
31 of 98
1 open now
Registered
95th of 98
by date
Lead sponsor
2 of 98
JW Pharmaceutical

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 68th largest by enrollment of the 97 interventional ones that give a count, is the only one that started in 2023, is one of 31 in phase 4, and was the 95th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

A multicenter, randomized, double-blind, phase Ⅳ study to evaluate the long-term efficacy and safety of Pitavastatin/Ezetimibe and Pitavastatin in patients with hypercholesterolemia with elevated triglycerides

Read the detailed description

A multicenter study to evaluate efficacy and safety

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • LDL Cholesterol Reduction
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with hypercholesterolemia
  • Patients diagnosed with metabolic syndrome or type 2 diabetes mellitus, and presenting with elevated LDL-C

Exclusion criteria

Exclusion Criteria:

  • New-onset acute cardio-cerebrovascular disease
  • Severe hepatic impairment
  • Active liver disease
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Pitavastatin/Ezetimibe Combination

    FDC of Pitavastatin/Ezetimibe

    Drug: Pitavastatin 4mg · Drug: Ezetimibe 10 mg · Drug: Placebo (for Pitavastatin)

  • Active comparator
    Pitavastatin Monotherapy

    Pitavastatin

    Drug: Pitavastatin 4mg · Drug: Placebo (for Pitavastatin/Ezetimibe)

Interventions

  • Administered as a fixed-dose combination tablet (Pitavastatin/Ezetimibe 4/10 mg) orally once daily for 52 weeks.

  • Administered as a fixed-dose combination tablet (Pitavastatin/Ezetimibe 4/10 mg) orally once daily for 52 weeks.

  • DrugPlacebo (for Pitavastatin/Ezetimibe)

    Administered as a matching placebo tablet identical in appearance to the Pitavastatin/Ezetimibe 4/10 mg fixed-dose combination, orally once daily for 52 weeks.

  • DrugPlacebo (for Pitavastatin)

    Administered as a matching placebo tablet identical in appearance to Pitavastatin 4 mg monotherapy, orally once daily for 52 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage change from baseline in LDL Cholesterol at Week 8 after the first dose of study treatment

    The unit of measure is percentage (%). The percentage change is calculated as: \[(Value at Week 8 - Value at Baseline) / Value at Baseline\] \* 100

    Time frame: Baseline to week 8

Secondary outcomes

  1. Change from baseline in HDL Cholesterol at Weeks 8, 24, and 52 after the first dose of study treatment

    Change = (Value at Week 8, 24, or 52) - (Value at Baseline), Unit of measure: mg/dL

    Time frame: Baseline to week 8, 24, 52

  2. Change from baseline in Triglycerides at Weeks 8, 24, and 52 after the first dose of study treatment

    Change = (Value at Week 8, 24, or 52) - (Value at Baseline), Unit of measure: mg/dL

    Time frame: Baseline to week 8, 24, 52

  3. Change from baseline in LDL Cholesterol at Weeks 8, 24, and 52 after the first dose of study treatment

    Change = (Value at Week 8, 24, or 52) - (Value at Baseline), Unit of measure: mg/dL

    Time frame: Baseline to week 8, 24, 52

  4. Change from baseline in Non-alcoholic Fatty Liver Disease Liver Fat Score (NLFS) at Weeks 24 and 52

    The NLFS is a calculated score used to estimate liver fat content. The change is calculated as (Value at Week 24 or 52) - (Value at Baseline).

    Time frame: Baseline to week 24, 52

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Jan 2026, 29 months.

Of 40 phase 4 interventional studies under Hypercholesterolemia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Mar 2, 2026
StartActual
Aug 21, 2023
Primary completionActual
Jan 22, 2026
CompletionEst.
Nov 30, 2026
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07442630
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Aug 21, 2023
Primary completion
Jan 22, 2026
Completion
Nov 30, 2026 (estimated)
Last update
Mar 2, 2026

Study contacts

Hyuk Sang Kwon
principal investigator · The Catholic University of Korea, Yeouido St. Mary's Hospital, Principal Investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ezetimibe

Start the discussion